MARKMD

IAPP on novel genetic and phenotypic markers of Parkinson's disease and Essential Tremor

Coordinatore	EBERHARD KARLS UNIVERSITAET TUEBINGEN    more  Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Dr. Nome: Holm Cognome: Graessner Email: send email Telefono: -2979307 Fax: -302250
Nazionalità Coordinatore	Germany [DE]
Totale costo	1˙173˙548 €
EC contributo	1˙173˙548 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IAPP-2008
Funding Scheme	MC-IAPP
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-03-01   -   2013-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	EBERHARD KARLS UNIVERSITAET TUEBINGEN  Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Dr. Nome: Holm Cognome: Graessner Email: send email Telefono: -2979307 Fax: -302250	DE (TUEBINGEN)	coordinator	595˙688.00
2	ISLENSK ERFDAGREINING EHF  Organization address address: Sturlugata 8 city: REYKJAVIK postcode: 101 contact info Titolo: Mr. Nome: Björgvin Cognome: Richardsson Email: send email Telefono: -2037 Fax: -2197	IS (REYKJAVIK)	participant	577˙860.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Copy number variations (CNV) are ubiquitously found throughout in the human genome. Their role in monogenic as well as multifactorial disorders as potential disease modifier is more and more stressed (Abecasis et al., 2007). In order to investigate the role of CNV in Parkinson’s disease (PD) and Essential Tremor (ET), two frequent neurological diseases, MARKMD brings together the unique expertises of deCODE genetics (Iceland) and University of Tübingen (Germany). On the one hand, deCODE genetics will contribute and transfer its unique genetic, epidemiologic and biostatistical expertise. The University of Tübingen, on the other hand, will contribute and transfer neuroimaging and clinical expertise in regard to PD and ET. Co-operation and transfer of knowledge is dedicated to the establishment of new tools for the detection of disease associated CNV and clinical markers in patients as well as healthy at-risk groups. Thus, we anticipate to come up with new neuroimaging/clinical and genetic markers relevant to the etiology and progression of PD and ET. Transfer of knowledge will be implemented through secondments, recruitments, and meetings. There will be a structured exchange of principle investigators from both partners at project milestones facilitating the training of newly recruited team members. All recruited project members will have workpackages at either partner which allows to disseminate project outcomes easily.'